Regulation of platelet lifespan by apoptosis

Platelets

Volumn 27, Issue 6, 2016, Pages 497-504

  Lebois, Marion ^a   Josefsson, Emma C ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; PHOSPHATIDYLSERINE; PROTEIN BCL 2;

ANIMAL; APOPTOSIS; BLOOD STORAGE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEMOSTASIS; HUMAN; MEGAKARYOCYTE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD PLATELETS; BLOOD PRESERVATION; CASPASES; GENE EXPRESSION REGULATION; HEMOSTASIS; HUMANS; MEGAKARYOCYTES; PHOSPHATIDYLSERINES; PLATELET TRANSFUSION; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 84964529927     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2016.1161739     Document Type: Review

References (120)

1. A.S.Weyrich Platelets:more than a sack of glue. Hematol/Educ Program Am Society Hematol Am Society Hematol Educ Program 2014;2014(1):400–403.
2. K.A.Ault, C.Knowles In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995;23(9):996–1001.
3. G.L.Dale, P.Friese, L.A.Hynes, S.A.Burstein Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995;85(7):1822–1825.
4. M.Michel Immune thrombocytopenia nomenclature, consensus reports, and guidelines:what are the consequences for daily practice and clinical research? Semin Hematol 2013;50(Suppl 1):S50–54.
5. D.J.Kuter Romiplostim. Can Treat Res 2011;157:267–288.
6. P.E.Czabotar, G.Lessene, A.Strasser, J.M.Adams Control of apoptosis by the BCL-2 protein family:implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15(1):49–63.
7. E.C.Josefsson, B.T.Kile Cell death in the hematopoietic system. In:X.-M.Yin, Z.Dong, editors. Essentials of apoptosis. 2nd ed. Humana Press, Springer, New York; 2009, p. 443–459.
8. J.F.Kerr, A.H.Wyllie, A.R.Currie Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Can 1972;26(4):239–257.
9. T.Kuwana, L.Bouchier-Hayes, J.E.Chipuk, C.Bonzon, B.A.Sullivan, D.R.Green, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17(4):525–535.
10. D.Ren, H.C.Tu, H.Kim, G.X.Wang, G.R.Bean, O.Takeuchi, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science (New York, NY) 2010;330(6009):1390–1393.
11. A.Villunger, V.Labi, P.Bouillet, J.Adams, A.Strasser Can the analysis of BH3-only protein knockout mice clarify the issue of ‘direct versus indirect’ activation of Bax and Bak? Cell Death Differ 2011;18(10):1545–1546.
12. S.N.Willis, J.I.Fletcher, T.Kaufmann, M.F.van Delft, L.Chen, P.E.Czabotar, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (New York, NY) 2007;315(5813):856–859.
13. C.Scaffidi, S.Fulda, A.Srinivasan, C.Friesen, F.Li, K.J.Tomaselli, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17(6):1675–1687.
14. P.J.Jost, S.Grabow, D.Gray, M.D.McKenzie, U.Nachbur, D.C.Huang, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009;460(7258):1035–1039.
15. N.Ben Amor, J.A.Pariente, G.M.Salido, A.Bartegi, J.A.Rosado Caspases 3 and 9 are translocated to the cytoskeleton and activated by thrombin in human platelets. Evidence for the involvement of PKC and the actin filament polymerization. Cell Signalling 2006;18(8):1252–1261.
16. V.Leytin, D.J.Allen, S.Mykhaylov, E.Lyubimov, J.Freedman Thrombin-triggered platelet apoptosis. J Thrombosis and Haemostasis:JTH 2006;4(12):2656–2663.
17. J.Li, Y.Xia, A.M.Bertino, J.P.Coburn, D.J.Kuter The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40(11):1320–1329.
18. D.M.Vanags, S.Orrenius, M.Aguilar-Santelises Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997;99(4):824–831.
19. B.B.Wolf, J.C.Goldstein, H.R.Stennicke, H.Beere, G.P.Amarante-Mendes, G.S.Salvesen, et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999;94(5):1683–1692.
20. K.D.Mason, M.R.Carpinelli, J.I.Fletcher, J.E.Collinge, A.A.Hilton, S.Ellis, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128(6):1173–1186.
21. H.Zhang, P.M.Nimmer, S.K.Tahir, J.Chen, R.M.Fryer, K.R.Hahn, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007;14(5):943–951.
22. K.U.Wagner, E.Claudio, E.B.Rucker, 3rd, G.Riedlinger, C.Broussard, P.L.Schwartzberg, et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development (Cambridge, England) 2000;127(22):4949–4958.
23. A.M.Bertino, X.Q.Qi, J.Li, Y.Xia, D.J.Kuter Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003;43(7):857–866.
24. E.C.Josefsson, C.James, K.J.Henley, M.A.Debrincat, K.L.Rogers, M.R.Dowling, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011;208(10):2017–2031.
25. T.Kodama, T.Takehara, H.Hikita, S.Shimizu, W.Li, T.Miyagi, et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010;138(7):2487–2498, 2498 e2481–2487.
26. T.Oltersdorf, S.W.Elmore, A.R.Shoemaker, R.C.Armstrong, D.J.Augeri, B.A.Belli, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435(7042):677–681.
27. C.Tse, A.R.Shoemaker, J.Adickes, M.G.Anderson, J.Chen, S.Jin, et al. ABT-263:a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68(9):3421–3428.
28. S.M.Schoenwaelder, Y.Yuan, E.C.Josefsson, M.J.White, Y.Yao, K.D.Mason, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009;114(3):663–666.
29. M.Vogler, H.A.Hamali, X.M.Sun, E.T.Bampton, D.Dinsdale, R.T.Snowden, et al. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011;117(26):7145–7154.
30. A.W.Roberts, J.F.Seymour, J.R.Brown, W.G.Wierda, T.J.Kipps, S.L.Khaw, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition:results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol:Off J Am Society Clin Oncol 2012;30(5):488–496.
31. S.M.Schoenwaelder, K.E.Jarman, E.E.Gardiner, M.Hua, J.Qiao, M.J.White, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118(6):1663–1674.
32. M.F.Koehler, P.Bergeron, E.F.Choo, K.Lau, C.Ndubaku, D.Dudley, et al. Structure-guided rescaffolding of selective antagonists of BCL-XL. ACS Med Chem Lett 2014;5(6):662–667.
33. G.Lessene, P.E.Czabotar, B.E.Sleebs, K.Zobel, K.N.Lowes, J.M.Adams, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol 2013;9(6):390–397.
34. Z.F.Tao, L.Hasvold, L.Wang, X.Wang, A.M.Petros, C.H.Park, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett 2014;5(10):1088–1093.
35. J.Suzuki, M.Umeda, P.J.Sims, S.Nagata Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010;468(7325):834–838.
36. J.D.Leverson, D.C.Phillips, M.J.Mitten, E.R.Boghaert, D.Diaz, S.K.Tahir, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015;7(279):279–240.
37. T.Lindsten, A.J.Ross, A.King, W.X.Zong, J.C.Rathmell, H.A.Shiels, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000;6(6):1389–1399.
38. T.Kodama, T.Takehara, H.Hikita, S.Shimizu, M.Shigekawa, W.Li, et al. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency:molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011;286(16):13905–13913.
39. C.Gieger, A.Radhakrishnan, A.Cvejic, W.Tang, E.Porcu, G.Pistis, et al. New gene functions in megakaryopoiesis and platelet formation. Nature 2011;480(7376):201–208.
40. J.H.Oh, Y.K.Kim, S.Moon, Y.J.Kim, B.J.Kim Genome-wide association study identifies candidate Loci associated with platelet count in Koreans. Genomics Inf 2014;12(4):225–230.
41. M.A.Debrincat, I.Pleines, M.Lebois, R.M.Lane, M.L.Holmes, J.Corbin, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis 2015;6:e1721.
42. S.Li, Z.Wang, Y.Liao, W.Zhang, Q.Shi, R.Yan, et al. The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. J Thrombosis Haemostasis:JTH 2010;8(2):341–350.
43. Z.J.Liu, K.M.Hoffmeister, Z.Hu, D.E.Mager, S.Ait-Oudhia, M.A.Debrincat, et al. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood 2014;123(22):3381–3389.
44. A.J.Souers, J.D.Leverson, E.R.Boghaert, S.L.Ackler, N.D.Catron, J.Chen, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202–208.
45. C.J.Vandenberg, E.C.Josefsson, K.J.Campbell, C.James, K.E.Lawlor, B.T.Kile, et al. Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice. Cell Death Diff 2014;21(5):676–684.
46. C.G.Print, K.L.Loveland, L.Gibson, T.Meehan, A.Stylianou, N.Wreford, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proceedings of the National Academy of Sciences of the United States of America 1998;95(21):12424–12431.
47. A.J.Ross, K.G.Waymire, J.E.Moss, A.F.Parlow, M.K.Skinner, L.D.Russell, et al. Testicular degeneration in Bclw-deficient mice. Nat Genet 1998;18(3):251–256.
48. A.Hamasaki, F.Sendo, K.Nakayama, N.Ishida, I.Negishi, K.Nakayama, et al. Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the bcl-2-related A1 gene. J Exp Med 1998;188(11):1985–1992.
49. E.Ottina, F.Grespi, D.Tischner, C.Soratroi, S.Geley, A.Ploner, et al. Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 2012;119(25):6032–6042.
50. M.A.Debrincat, E.C.Josefsson, C.James, K.J.Henley, S.Ellis, M.Lebois, et al. Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood 2012;119(24):5850–5858.
51. T.Kodama, H.Hikita, T.Kawaguchi, M.Shigekawa, S.Shimizu, Y.Hayashi, et al. Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ 2012;19(11):1856–1869.
52. E.C.Josefsson, D.L.Burnett, M.Lebois, M.A.Debrincat, M.J.White, K.J.Henley, et al. Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways. Nat Commun 2014;5:3455.
53. L.M.Lien, C.C.Su, W.H.Hsu, W.J.Lu, C.L.Chung, T.L.Yen, et al. Mechanisms of andrographolide-induced platelet apoptosis in human platelets:regulatory roles of the extrinsic apoptotic pathway. Phytotherapy Research:PTR 2013;27(11):1671–1677.
54. K.H.Lin, G.Hsiao, C.M.Shih, D.S.Chou, J.R.Sheu Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res 2009;83(3):575–585.
55. J.J.Lopez, G.M.Salido, J.A.Pariente, J.A.Rosado Thrombin induces activation and translocation of Bid, Bax and Bak to the mitochondria in human platelets. J Thrombosis Haemostasis:JTH 2008;6(10):1780–1788.
56. P.N.Kelly, M.J.White, M.W.Goschnick, K.A.Fairfax, D.M.Tarlinton, S.A.Kinkel, et al. Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death and Differentiation 2010;17(10):1655–1664.
57. S.Plenchette, M.Moutet, M.Benguella, J.P.N’Gondara, F.Guigner, C.Coffe, et al. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia 2001;15(10):1572–1581.
58. A.Mutlu, A.V.Gyulkhandanyan, J.Freedman, V.Leytin Activation of caspases-9, -3 and -8 in human platelets triggered by BH3-only mimetic ABT-737 and calcium ionophore A23187:caspase-8 is activated via bypass of the death receptors. Br J Haematol 2012;159(5):565–571.
59. D.Vucic, V.M.Dixit, I.E.Wertz Ubiquitylation in apoptosis:a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biology 2011;12(7):439–452.
60. R.I.Schleicher, F.Reichenbach, P.Kraft, A.Kumar, M.Lescan, F.Todt, et al. Platelets induce apoptosis via membrane-bound FasL. Blood 2015;126(12):1483–1493.
61. M.J.White, S.M.Schoenwaelder, E.C.Josefsson, K.E.Jarman, K.J.Henley, C.James, et al. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood 2012;119(18):4283–4290.
62. M.F.van Delft, D.P.Smith, M.H.Lahoud, D.C.Huang, J.M.Adams Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death Differ 2010;17(5):821–832.
63. M.J.White, K.McArthur, D.Metcalf, R.M.Lane, J.C.Cambier, M.J.Herold, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 2014;159(7):1549–1562.
64. S.Nagata, R.Hanayama, K.Kawane Autoimmunity and the clearance of dead cells. Cell 2010;140(5):619–630.
65. E.O.Agbani, M.T.van den Bosch, E.Brown, C.M.Williams, N.J.Mattheij, J.M.Cosemans, et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation 2015;132(15):1414–1424.
66. E.M.Bevers, P.Comfurius, J.L.van Rijn, H.C.Hemker, R.F.Zwaal Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. European Journal of Biochemistry/FEBS 1982;122(2):429–436.
67. S.M.de Witt, R.Verdoold, J.M.Cosemans, J.W.Heemskerk Insights into platelet-based control of coagulation. Thrombosis Res 2014;133(Suppl 2):S139–S148.
68. J.Suzuki, D.P.Denning, E.Imanishi, H.R.Horvitz, S.Nagata Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science (New York, NY) 2013;341(6144):403–406.
69. K.M.Hoffmeister The role of lectins and glycans in platelet clearance. Journal of Thrombosis and Haemostasis:JTH 2011;9(Suppl 1):35–43.
70. R.Grozovsky, S.Giannini, H.Falet, K.M.Hoffmeister Regulating billions of blood platelets:glycans and beyond. Blood 2015;126(16):1877–1884.
71. G.J.Gasic, T.B.Gasic, C.C.Stewart Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences of the United States of America 1968;61(1):46–52.
72. J.P.Greenberg, M.A.Packham, M.A.Guccione, M.L.Rand, H.J.Reimers, J.F.Mustard Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood 1979;53(5):916–927.
73. P.E.Stenberg, J.Levin, G.Baker, Y.Mok, L.Corash Neuraminidase-induced thrombocytopenia in mice:effects on thrombopoiesis. J Cell Physiol 1991;147(1):7–16.
74. H.F.Kotze, V.van Wyk, P.N.Badenhorst, A.D.Heyns, J.P.Roodt, M.G.Lotter Influence of platelet membrane sialic acid and platelet-associated IgG on ageing and sequestration of blood platelets in baboons. Thrombosis and Haemostasis 1993;70(4):676–680.
75. A.L.Sorensen, V.Rumjantseva, S.Nayeb-Hashemi, H.Clausen, J.H.Hartwig, H.H.Wandall, et al. Role of sialic acid for platelet life span:exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009;114(8):1645–1654.
76. V.Rumjantseva, P.K.Grewal, H.H.Wandall, E.C.Josefsson, A.L.Sorensen, G.Larson, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009;15(11):1273–1280.
77. R.Grozovsky, A.J.Begonja, K.Liu, G.Visner, J.H.Hartwig, H.Falet, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015;21(1):47–54.
78. V.Leytin Apoptosis in the anucleate platelet. Blood Rev 2012;26(2):51–63.
79. K.BTKile. The role of apoptosis in megakaryocytes and platelets. British J Haematol 2014;165(2):217–226.
80. B.F.Kraemer, R.A.Campbell, H.Schwertz, Z.G.Franks, Vieira de Abreu A, Grundler K, et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood 2012;120(25):5014–5020.
81. J.J.Yeh, S.Tsai, D.C.Wu, J.Y.Wu, T.C.Liu, A.Chen P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection. Blood 2010;115(21):4247–4253.
82. M.T.Alonzo, T.L.Lacuesta, E.M.Dimaano, T.Kurosu, L.A.Suarez, C.A.Mapua, et al. Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. J Infect Dis 2012;205(8):1321–1329.
83. E.D.Hottz, M.F.Oliveira, P.C.Nunes, R.M.Nogueira, R.Valls-de-Souza, A.T.Da Poian, et al. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. J Thrombosis and Haemostasis:JTH 2013;11(5):951–962.
84. K.B.Clark, S.Noisakran, N.Onlamoon, H.M.Hsiao, J.Roback, F.Villinger, et al. Multiploid CD61+ cells are the pre-dominant cell lineage infected during acute dengue virus infection in bone marrow. PLos One 2012;7(12):e52902.
85. G.Zauli, L.Catani, D.Gibellini, M.C.Re, N.Vianelli, V.Colangeli, et al. Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematology 1996;92(3):711–717.
86. D.Zucker-Franklin, C.S.Termin, M.C.Cooper Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1). Am J Pathol 1989;134(6):1295–1303.
87. E.J.Houwerzijl, N.R.Blom, J.J.van der Want, M.T.Esselink, J.J.Koornstra, J.W.Smit, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103(2):500–506.
88. J.Winkler, S.Kroiss, M.L.Rand, I.Azzouzi, K.W.Annie Bang, O.Speer, et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol 2012;156(4):508–515.
89. J.D.Wang, T.T.Ou, C.J.Wang, T.K.Chang, H.J.Lee Platelet apoptosis resistance and increased CXCR4 expression in pediatric patients with chronic immune thrombocytopenic purpura. Thrombosis Res 2010;126(4):311–318.
90. M.Martin, R.de Paz, V.Jimenez-Yuste, I.Fernandez Bello, Garcia Arias Salgado E, Alvarez MT, et al. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. Thrombosis Haemostasis 2013;109(5):909–919.
91. E.J.Houwerzijl, N.R.Blom, J.J.van der Want, E.Vellenga, J.T.de Wolf Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006;20(11):1937–1942.
92. J.Bao, L.Lin Platelet apoptosis in patients with acute coronary syndromes. J Thrombosis Thrombolysis 2015;39(4):539–546.
93. R.Singhal, G.K.Annarapu, A.Pandey, S.Chawla, A.Ojha, A.Gupta, et al. Hemoglobin interaction with GP1balpha induces platelet activation and apoptosis:a novel mechanism associated with intravascular hemolysis. Haematologica 2015;100(12):1526–1533.
94. W.H.Wilson, O.A.O’Connor, M.S.Czuczman, A.S.LaCasce, J.F.Gerecitano, J.P.Leonard, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies:a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11(12):1149–1159.
95. C.J.Vandenberg, S.Cory ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013;121(12):2285–2288.
96. L.Gandhi, D.R.Camidge, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol:Off J Am Society of Clinical Oncology 2011;29(7):909–916.
97. C.M.Rudin, C.L.Hann, E.B.Garon, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical Cancer Research:An official journal of the American Association for Cancer Research 2012;18(11):3163–3169.
98. J.Levin, C.L.Conley Thrombocytosis associated with malignant disease. Arch Internal Med 1964;114:497–500.
99. L.J.Gay, B.Felding-Habermann Contribution of platelets to tumour metastasis. Nat Rev Can 2011;11(2):123–134.
100. R.L.Stone, A.M.Nick, I.A.McNeish, F.Balkwill, H.D.Han, J.Bottsford-Miller, et al. Paraneoplastic thrombocytosis in ovarian cancer. New England J Med 2012;366(7):610–618.
101. I.Dominguez, S.Crippa, S.P.Thayer, Y.P.Hung, C.R.Ferrone, A.L.Warshaw, et al. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008;32(6):1051–1056.
102. T.Guo, M.Krzystanek, Z.Szallasi, A.Szallasi Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Research 2014;3:180.
103. M.Ikeda, H.Furukawa, H.Imamura, J.Shimizu, H.Ishida, S.Masutani, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9(3):287–291.
104. L.M.Pedersen, N.Milman Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996;9(9):1826–1830.
105. K.Sasaki, K.Kawai, N.H.Tsuno, E.Sunami, J.Kitayama Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012;36(1):192–200.
106. R.Suppiah, P.E.Shaheen, P.Elson, S.A.Misbah, L.Wood, R.J.Motzer, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006;107(8):1793–1800.
107. M.Tomita, T.Shimizu, M.Hara, T.Ayabe, T.Onitsuka Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interactive Cardiovascular and Thoracic Surgery 2008;7(4):613–615.
108. K.M.Hoffmeister, E.C.Josefsson, N.A.Isaac, H.Clausen, J.H.Hartwig, T.P.Stossel Glycosylation restores survival of chilled blood platelets. Science (New York, NY) 2003;301(5639):1531–1534.
109. H.Ohto, K.E.Nollet Overview on platelet preservation:better controls over storage lesion. Transfusion and Apheresis Science:Official Journal of the World Apheresis Association:Official Journal of the European Society for Haemapheresis 2011;44(3):321–325.
110. J.P.Cazenave, H.Isola, C.Waller, I.Mendel, D.Kientz, M.Laforet, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center:impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51(3):622–629.
111. P.S.Hartley, J.Savill, S.B.Brown The death of human platelets during incubation in citrated plasma involves shedding of CD42b and aggregation of dead platelets. Thrombosis Haemostasis 2006;95(1):100–106.
112. G.Soslau, J.Giles The loss of sialic acid and its prevention in stored human platelets. Thrombosis Res 1982;26(6):443–455.
113. A.J.Jansen, E.C.Josefsson, V.Rumjantseva, Q.P.Liu, H.Falet, W.Bergmeier, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice. Blood 2012;119(5):1263–1273.
114. A.M.Albanyan, P.Harrison, M.F.Murphy Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009;49(1):108–117.
115. P.Cookson, J.Sutherland, C.Turner, S.Bashir, M.Wiltshire, V.Hancock, et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfusion Med (Oxford, England) 2010;20(6):392–402.
116. W.B.Mitchell, M.P.Pinheiro, N.Boulad, D.Kaplan, M.N.Edison, B.Psaila, et al. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol 2014;89(12):E228–E234.
117. J.M.Burkhart, M.Vaudel, S.Gambaryan, S.Radau, U.Walter, L.Martens, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012;120(15):e73–e82.
118. rd ed. Elsevier, San Diego; 2013, p. 51–66.
119. M.C.Clarke, J.Savill, D.B.Jones, B.S.Noble, S.B.Brown Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003;160(4):577–587.
120. K.H.Lin, H.C.Chang, W.J.Lu, T.Jayakumar, H.C.Chou, T.H.Fong, et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-activating agents. Platelets 2009;20(8):575–581.